- Home
- LQDA
LQDA
Liquidia Corporation
as 10-31-2025 9:57am EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Upcoming Earnings Alert:
Get ready for potential market movements as Liquidia Corporation LQDA prepares to release earnings report on 03 Nov 2025.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 1.9B | IPO Year: | 2018 |
| Target Price: | $32.67 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.71 - $29.94 | Next Earning Date: | 11-03-2025 |
| Revenue: | $19,322,000 | Revenue Growth: | 30.20% |
| Revenue Growth (this year): | 424.31% | Revenue Growth (next year): | 359.32% |
Stock Insider Trading Activity of Liquidia Corporation (LQDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Adair Jason | LQDA | Chief Business Officer | Oct 27 '25 | Sell | $22.93 | 692 | $15,867.56 | 174,998 | |
| Boyle Dana | LQDA | Chief Accounting Officer | Oct 27 '25 | Sell | $22.93 | 1,073 | $24,603.89 | 184,338 | |
| Moomaw Scott | LQDA | Chief Commercial Officer | Oct 13 '25 | Sell | $23.41 | 4,900 | $114,709.00 | 153,462 | |
| JEFFS ROGER | LQDA | Chief Executive Officer | Oct 13 '25 | Sell | $23.41 | 20,261 | $474,310.01 | 1,032,973 | |
| Kaseta Michael | LQDA | CFO and COO | Oct 13 '25 | Sell | $23.41 | 11,630 | $272,258.30 | 352,646 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Oct 13 '25 | Sell | $23.41 | 5,327 | $124,705.07 | 247,930 | |
| Adair Jason | LQDA | Chief Business Officer | Oct 13 '25 | Sell | $23.41 | 3,670 | $85,914.70 | 174,998 | |
| Schundler Russell | LQDA | General Counsel | Oct 13 '25 | Sell | $23.41 | 7,839 | $183,510.99 | 576,017 | |
| Krepp Sarah | LQDA | Chief Human Resource Officer | Oct 13 '25 | Sell | $23.41 | 1,691 | $39,586.31 | 141,439 | |
| Boyle Dana | LQDA | Chief Accounting Officer | Oct 13 '25 | Sell | $23.41 | 1,238 | $28,981.58 | 184,338 |
Latest Liquidia Corporation News
LQDA Breaking Stock News: Dive into LQDA Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Is IPF the Next Big Market Opportunity for United Therapeutics?
Simply Wall St.
a month ago
3 Growth Companies With High Insider Ownership Seeing Up To 63% Revenue Growth
Insider Monkey
2 months ago
Jefferies Highlights Yutrepia’s Market Edge in Supporting a Buy on Liquidia (LQDA)
Insider Monkey
2 months ago
Court Victory and Fresh Funding Propel Growth at Liquidia Corporation
MT Newswires
4 months ago
BTIG Cuts Price Target on Liquidia to $40 From $45, Maintains Buy Rating
MT Newswires
4 months ago
Liquidia Gets $50 Million From Healthcare Royalty
GlobeNewswire
4 months ago
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
Simply Wall St.
4 months ago
Top Growth Companies With Insider Stakes In June 2025
Compare LQDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.